Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. on July 21, 2016. The report details the publication of a clinical trial paper by The American Academy of Ophthalmology regarding the company's Argus II Retinal Prosthesis System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements.
Material Changes
The material event reported is the publication of five-year safety and performance data for the Argus II system. The study assessed 30 subjects across 10 centers in the United States and Europe who were blind due to retinitis pigmentosa or similar disorders.
Outlook, Commentary, and Risks
- Clinical Results: The five-year study demonstrated that patients' visual function improved after implantation and these improvements were sustained over the five-year period.
- Safety Profile: Results indicated that the Argus II system maintained an acceptable safety profile.
- Patient Impact: Patients reported a positive impact on wellbeing, including a renewed connection with loved ones and their environment.
- Exhibits: The filing incorporates a press release (Exhibit 99.1) and the full clinical trial paper (Exhibit 99.2) by reference.
Investor Verification Checklist
- Review Exhibit 99.2 for the full methodology and statistical data of the five-year clinical trial.
- Verify the specific definition of "visual function improvement" used in the study.
- Confirm the regulatory status of the Argus II system in the jurisdictions where the trial was conducted.
- Assess the commercial implications of the sustained safety and performance data on future sales projections.